February 14, 2019 7:31am

One of my focuses is indication analysis. An indication can be a development of almost any kind and many not of good timing …

Caladrius Biosciences (CLBS) reported top-line data of a 1-year follow-up data CLBS03’s P2b that was well tolerated at the doses tested in the study; however, there was NO improvement in the primary endpoint of preservation of C-peptide levels vs. placebo at 1 year was observed at the group level. There is a negative -$1.22 or -22.86% aftermarket indication.

Pre-open indications:  1 BUY, 3 SELLs and 3 TRADEs


Presenting alternative hypotheses clarifies material facts and evidence available to investors. “Devil’s Advocacy” also provides greater confidence that the current sector outlook will hold-up to close scrutiny!

The remainder of the month’s trading sessions will be critical for the RegMed sector which will establish whether market reaction to recent events is temporary and short-lived, or if this is a continuation of a more fundamental correction. 


U.S. stock index futures are awake and moving

Dow futures are UP +0.38% (+96 points) and NASDAQ futures are UP +0.42% (+29 points)


Futures move higher on US-China trade optimism;

European stocks were higher amid a flurry of earnings results;

Asia markets were subdued as investors wait for concrete developments in US-China trade talks


Data docket: Retail sales are expected at 8.30 a.m. ET with jobless claims and core PPI due at the same time.


Thursday’s indications in the pre-market:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating

The SPDR S&P Biotech ETF (XBI) is NOT indicating

The Health Care Select Sector SPDR ETF (XLV) is indicating a POSITIVE +0.032% UPSIDE

The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.08% UPSIDE



Today is the 10th session in February and so far there are nine (9) sessions, four (4) negative endeavored five (5) positive closes while volume remains LOW … with 4 out of the 19 upside had higher (than the 3 month average) volume  and 0 out of the 25 downside experienced greater volume (than the 3 month average).

I am concerned as the percentage spreads from the close ranged from the 19 upside at +0.02% (BMRN) to +5.88% (ONVO) while the 25 downside ranged from -0.06% (ONCE) to -5.88% (QURE) with 1 flat close (RENE.L).

The IBB has advanced in the last four (4) sessions: +0.30%, +1%, +0.50% and +0.63% on last Friday – getting TOPPY as one (1) negative event seems to drop the sector.

Also there was drama in the sector as it opened with a positive Advance/Decline Line (A/DL) of 29/14 and 2 flats and closed negative with an A/DL of 19/25 and 1 flat …



From last night's post, “résistance - the sector surrendered in sight of the wall of worry, another I told you so!”


Companies in my headlights – It’s your decision; I provide an idea and context:

bluebird bio (BLUE) closed up +$0.36 to $135.62 and has seen $130.75 (2/8) and $130.16 (1/30) twice while starting January at $99.50. RICH and a candidate before quarterly results – SELL;

Caladrius Biosciences (CLBS) closed up +$0.09 to $5.34 and has a negative -$1.22 or -22.86% aftermarket indication. (See title). What’s CEO Mazzo done (?) other than sell-off PCT to Hitachi, move the company to “Polo” land while embarking on a spending spree– SELL;

I hate to have to harp on specific companies so often: as I have stated this peer group is a trading vehicle …

CRISPER Therapeutics (CRSP) closed down -$0.53 to $31.11 after Tuesday’s +$0.51 and Monday’s +$0.74. CRSP has a positive +$0.17 or +0.55% aftermarket indication. The overbought become the oversold and bounce back – TRADE;

Editas Medicine (EDIT) closed down -$0.34 to $19.95 after Tuesday’s +$0.32 after Monday’s +$0.22. EDIT has a negative -$0.06 or -0.30% aftermarket indication – TRADE;

Intellia Therapeutics (NTLA) closed down -$0.17 to $13.75 after Tuesday’s +$0.21 and Monday’s +$0.27 without any indication – TRADE;

Solid Biosciences (SLDB) closed up +$0.74 to $8.33 and has a negative -$0.33 or -3.96% aftermarket indication following a 67.82 % dive based on 2/7’s evaluation of the SGT-001 in a DMD (Duchenne muscular dystrophy) indication which were NOT very encouraging. A trading TOY and NO new news to back-up ANY upside post the FALL from the data release – SELL;

Verastem (VSTM) closed down -$0.02 to $3.10 and announced that results of the P2 DYNAMO™ study, which evaluated COPIKTRA™ (duvelisib) capsules in patients with indolent non-Hodgkin lymphoma (iNHL) who were refractory to both rituximab and chemotherapy or radio-immunotherapy, was published online in the [peer-reviewed] Journal of Clinical Oncology – BUY;.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.